Inovio Pharmaceuticals (INO) Competitors

Inovio Pharmaceuticals logo
$1.61 -0.02 (-0.98%)
As of 09:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

INO vs. MRNA, ABUS, GERN, CLYM, and WVE

Should you buy Inovio Pharmaceuticals stock or one of its competitors? Inovio Pharmaceuticals's main competitors and comparable companies include Moderna (MRNA), Arbutus Biopharma (ABUS), Geron (GERN), Climb Bio (CLYM), and WAVE Life Sciences (WVE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Inovio Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Inovio Pharmaceuticals (NASDAQ:INO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Moderna has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Moderna had 18 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 39 mentions for Moderna and 21 mentions for Inovio Pharmaceuticals. Moderna's average media sentiment score of 0.40 beat Inovio Pharmaceuticals' score of 0.34 indicating that Moderna is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Moderna
8 Very Positive mention(s)
8 Positive mention(s)
12 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Neutral
Inovio Pharmaceuticals
4 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -110.46%. Moderna's return on equity of -25.79% beat Inovio Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Moderna-110.46% -25.79% -15.85%
Inovio Pharmaceuticals N/A -28,886.30%-75.67%

Moderna currently has a consensus price target of $120.25, suggesting a potential downside of 41.85%. Inovio Pharmaceuticals has a consensus price target of $6.33, suggesting a potential upside of 288.55%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moderna
4 Sell rating(s)
15 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.08
Inovio Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Inovio Pharmaceuticals has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$1.94B43.04-$2.82B-$7.10N/A
Inovio Pharmaceuticals$60K2,993.22-$84.95M-$0.54N/A

Summary

Moderna beats Inovio Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Arbutus Biopharma?

Inovio Pharmaceuticals (NASDAQ:INO) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Inovio Pharmaceuticals has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

In the previous week, Inovio Pharmaceuticals had 20 more articles in the media than Arbutus Biopharma. MarketBeat recorded 21 mentions for Inovio Pharmaceuticals and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.20 beat Inovio Pharmaceuticals' score of 0.34 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inovio Pharmaceuticals
4 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arbutus Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Inovio Pharmaceuticals currently has a consensus target price of $6.33, indicating a potential upside of 288.55%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Inovio Pharmaceuticals is more favorable than Arbutus Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inovio Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Arbutus Biopharma
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Arbutus Biopharma has a net margin of 121.17% compared to Inovio Pharmaceuticals' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.12% beat Inovio Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Inovio PharmaceuticalsN/A -28,886.30% -75.67%
Arbutus Biopharma 121.17%129.12%89.26%

Arbutus Biopharma has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inovio Pharmaceuticals$60K2,993.22-$84.95M-$0.54N/A
Arbutus Biopharma$14.08M44.09-$33.50M$1.133.58

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Arbutus Biopharma beats Inovio Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Geron?

Geron (NASDAQ:GERN) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Geron has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market.

73.7% of Geron shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 1.7% of Geron shares are held by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Inovio Pharmaceuticals had 16 more articles in the media than Geron. MarketBeat recorded 21 mentions for Inovio Pharmaceuticals and 5 mentions for Geron. Geron's average media sentiment score of 0.86 beat Inovio Pharmaceuticals' score of 0.34 indicating that Geron is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Geron
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Inovio Pharmaceuticals
4 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Inovio Pharmaceuticals has a net margin of 0.00% compared to Geron's net margin of -23.04%. Geron's return on equity of -16.29% beat Inovio Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Geron-23.04% -16.29% -6.82%
Inovio Pharmaceuticals N/A -28,886.30%-75.67%

Geron presently has a consensus target price of $3.75, suggesting a potential upside of 275.00%. Inovio Pharmaceuticals has a consensus target price of $6.33, suggesting a potential upside of 288.55%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Geron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
Inovio Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Geron has higher revenue and earnings than Inovio Pharmaceuticals. Geron is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$183.88M3.50-$83.50M-$0.08N/A
Inovio Pharmaceuticals$60K2,993.22-$84.95M-$0.54N/A

Summary

Geron and Inovio Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Climb Bio?

Inovio Pharmaceuticals (NASDAQ:INO) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

In the previous week, Inovio Pharmaceuticals had 11 more articles in the media than Climb Bio. MarketBeat recorded 21 mentions for Inovio Pharmaceuticals and 10 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.72 beat Inovio Pharmaceuticals' score of 0.34 indicating that Climb Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inovio Pharmaceuticals
4 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Climb Bio
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Inovio Pharmaceuticals has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

Climb Bio's return on equity of -30.57% beat Inovio Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Inovio PharmaceuticalsN/A -28,886.30% -75.67%
Climb Bio N/A -30.57%-29.55%

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Inovio Pharmaceuticals currently has a consensus price target of $6.33, indicating a potential upside of 288.55%. Climb Bio has a consensus price target of $28.14, indicating a potential upside of 187.76%. Given Inovio Pharmaceuticals' higher probable upside, equities research analysts clearly believe Inovio Pharmaceuticals is more favorable than Climb Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inovio Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Climb Bio
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.00

Climb Bio has lower revenue, but higher earnings than Inovio Pharmaceuticals. Climb Bio is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inovio Pharmaceuticals$60K2,993.22-$84.95M-$0.54N/A
Climb BioN/AN/A-$59.85M-$0.82N/A

Summary

Climb Bio beats Inovio Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Inovio Pharmaceuticals had 13 more articles in the media than WAVE Life Sciences. MarketBeat recorded 21 mentions for Inovio Pharmaceuticals and 8 mentions for WAVE Life Sciences. Inovio Pharmaceuticals' average media sentiment score of 0.34 beat WAVE Life Sciences' score of -0.23 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
WAVE Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inovio Pharmaceuticals
4 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Inovio Pharmaceuticals has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -296.86%. WAVE Life Sciences' return on equity of -44.66% beat Inovio Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
WAVE Life Sciences-296.86% -44.66% -36.80%
Inovio Pharmaceuticals N/A -28,886.30%-75.67%

WAVE Life Sciences currently has a consensus target price of $20.44, indicating a potential upside of 619.87%. Inovio Pharmaceuticals has a consensus target price of $6.33, indicating a potential upside of 288.55%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe WAVE Life Sciences is more favorable than Inovio Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WAVE Life Sciences
1 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
2.90
Inovio Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Inovio Pharmaceuticals has lower revenue, but higher earnings than WAVE Life Sciences. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WAVE Life Sciences$42.73M13.11-$204.38M-$1.07N/A
Inovio Pharmaceuticals$60K2,993.22-$84.95M-$0.54N/A

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

WAVE Life Sciences has a beta of -1.4, meaning that its share price is 240% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

Summary

WAVE Life Sciences beats Inovio Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Inovio Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INO vs. The Competition

MetricInovio PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$177.06M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-2.9826.7033.9728.44
Price / Sales2,963.8415.788.495.70
Price / CashN/A22.9521.0121.90
Price / Book-5.214.184.453.72
Net Income-$84.95M-$24.15M$3.52B$393.10M
7 Day Performance9.42%-7.79%-5.94%-5.77%
1 Month Performance63.01%-5.95%-4.58%-7.14%
1 Year Performance-14.60%-8.08%-1.95%-7.47%

Inovio Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INO
Inovio Pharmaceuticals
3.0061 of 5 stars
$1.61
-1.0%
$6.33
+292.4%
-17.7%$177.06M$60KN/A112
MRNA
Moderna
1.395 of 5 stars
$216.68
-3.0%
$113.75
-47.5%
+735.2%$87.69B$2.52BN/A4,700
ABUS
Arbutus Biopharma
1.3333 of 5 stars
$4.11
+0.4%
N/A-10.8%$629.26M$14.08M3.6319
GERN
Geron
3.9381 of 5 stars
$0.97
+0.4%
$3.75
+286.2%
-11.5%$625.56M$183.88MN/A258
CLYM
Climb Bio
2.9608 of 5 stars
$10.19
-1.6%
$28.14
+176.2%
+420.2%$598.54MN/AN/A29

Related Companies and Tools


This page (NASDAQ:INO) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners